IOL Chemicals and Pharmaceuticals Limited (IOL), manufacturer of active pharmaceutical ingredients (APIs) and specialty chemicals, has received regulatory approval from China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for its Ibuprofen API. The approval authorizes IOL to export Ibuprofen to the Chinese market, marking a key milestone in the company’s international growth strategy.
Expanding Access to Widely Used Pain Relief Drug
People extensively use Ibuprofen, a well-known non-steroidal anti-inflammatory drug (NSAID), for pain relief, reducing inflammation, and controlling fever. With this certification in place, IOL can now cater to China’s growing demand for high-quality APIs, solidifying its presence in one of the world’s largest pharmaceutical markets.
Diversified Portfolio and Global Expansion
IOL continues to strengthen its global footprint with a diversified API portfolio of over thirteen products, including metformin hydrochloride, clopidogrel bisulfate form II, pantoprazole sodium, and losartan potassium.
As per the press release, the company remains focused on expanding international reach through quality-driven manufacturing practices and regulatory compliance, further positioning itself as a trusted supplier in the global pharmaceutical ecosystem.
